Skip to main content
PMC home page
PLOS ONE logoLink to PLOS ONE
. 2019 Nov 4;14(11):e0224674. doi: 10.1371/journal.pone.0224674

Carvedilol improves glucose tolerance and insulin sensitivity in treatment of adrenergic overdrive in high fat diet-induced obesity in mice

Linh V Nguyen 1, Quang V Ta 2, Thao B Dang 1,¤a, Phu H Nguyen 3, Thach Nguyen 1,¤b, Thi Van Huyen Pham 1, Trang HT Nguyen 4, Stephen Baker 4, Trung Le Tran 5, Dong Joo Yang 5, Ki Woo Kim 5,*, Khanh V Doan 1,*
Editor: Dong-Gyu Jo6
PMCID: PMC6827914  PMID: 31682617

Abstract

Catecholamine excess reflecting an adrenergic overdrive of the sympathetic nervous system (SNS) has been proposed to link to hyperleptinemia in obesity and may contribute to the development of metabolic disorders. However, relationship between the catecholamine level and plasma leptin in obesity has not yet been investigated. Moreover, whether pharmacological blockade of the adrenergic overdrive in obesity by the third-generation beta-blocker agents such as carvedilol could help to prevent metabolic disorders is controversial and remains to be determined. Using the high fat diet (HFD)-induced obese mouse model, we found that basal plasma norepinephrine, the principal catecholamine as an index of SNS activity, was persistently elevated and highly correlated with plasma leptin concentration during obesity development. Targeting the adrenergic overdrive from this chronic norepinephrine excess in HFD-induced obesity with carvedilol, a third-generation beta-blocker with vasodilating action, blunted the HFD-induced hepatic glucose over-production by suppressing the induction of gluconeogenic enzymes, and enhanced the muscular insulin signaling pathway. Furthermore, carvedilol treatment in HFD-induced obese mice decreased the enlargement of white adipose tissue and improved the glucose tolerance and insulin sensitivity without affecting body weight and blood glucose levels. Our results suggested that catecholamine excess in obesity might directly link to the hyperleptinemic condition and the therapeutic targeting of chronic adrenergic overdrive in obesity with carvedilol might be helpful to attenuate obesity-related metabolic disorders.

Introduction

Obesity and related adverse consequences such as metabolic disorders and cardiovascular diseases (CVDs) have become a global health problem in modern society [1]. Overactivation of the sympathetic nervous system (SNS) which has been well-documented in obesity [2] plays an important role in the pathogenesis of obesity-associated CVDs [3, 4] and may also contribute to the development of metabolic disorders in obesity [5–7]. Compelling evidence has suggested that the hyperleptinemic condition (increased plasma leptin concentration) in obesity is one of important factors contributing to the hyper-activated SNS which eventually leads to many cardiovascular complications [3, 8–10].

Recent studies have shown that the metabolic and cardiovascular effects of leptin might be mediated via an increase in catecholamine signaling [11–14], possibly via modulating the synthesis and release of catecholamine [15–21]. As final mediators of the SNS activity, catecholamine plays a crucial role in the physiology of neurotransmission, physical and mental activities, cardiovascular function, metabolism, inflammation and immunity [22–24]. However, catecholamine excess which leads to adrenergic receptor overactivation is known to cause profoundly adverse effects on metabolism and cardiovascular function as seen in patients with pheochromocytoma [25, 26]. Nonetheless, whether catecholamine excess is observed in obesity and links to hyperleptinemia has not yet been investigated. Moreover, it remains controversial whether targeting the SNS hyperactivity in obesity by pharmacological treatment could help to prevent metabolic disorders [6].

Beta-blockers, available therapeutic agents in clinical treatment of many cardiovascular diseases, competitively antagonize endogenous catecholamine on β-adrenergic receptors of the SNS [27, 28]. Beta-blockers are classified into first, second, and third generation depending on their β1/β2-adrenoceptor selectivity and intrinsic vasodilatory properties [27]. Even though it seems reasonable that blocking the SNS hyperactivity in patients with obesity/metabolic syndrome might provide metabolic benefits, the clinical use of traditional beta-blockers (first and second generation agents) such as atenolol in these patients is concerning due to their negative metabolic effects including glucose intolerance, dyslipidemia, and inability to lose weight [29, 30]. It has been suggested that the third-generation beta-blockers which possess vasodilating properties either by an additive α-adrenoceptor antagonism or a nitric oxide-synthesizing stimulation provide complete sympathetic blockade and may mitigate the negative metabolic effects of traditional beta-blockers [31]. This notion was supported by results from recent clinical studies showing neutral to favorable effects of the third-generation beta-blockers on metabolic profiles compared to traditional beta-blockers [32, 33]. However, molecular metabolic effects on the glucose tolerance and insulin sensitivity of these newer beta-blockers in obesity have not been investigated.

In the present study, we found that basal plasma norepinephrine, the principal catecholamine as an index of SNS activity [34], was persistently elevated and highly correlated with the plasma leptin concentration, but not plasma insulin, during high fat diet (HFD)-induced obesity in mice. Targeting the adrenergic overdrive from this chronic norepinephrine excess in HFD-induced obesity with carvedilol, a third-generation beta-blocker agent with additive α1-adrenoceptor antagonizing action [35, 36], blunted hepatic glucose overproduction by suppressing the induction of gluconeogenic enzymes and increased the muscular insulin signaling pathway. These metabolic effects eventually led to an improvement in glucose tolerance and insulin sensitivity. These results suggested a high correlation between chronic norepinephrine excess and hyperleptinemia in obesity and the therapeutic treatment of chronic adrenergic overdrive with carvedilol might be helpful to attenuate the glucose and insulin intolerance associated with obesity.

Materials and methods

Antibodies and reagents

Primary antibodies including Akt (Cat. No. 2920, dilution 1:10,000), p-Akt (Cat. No. 3787, dilution 1:10,000), Creb (Cat. No. 9197, dilution 1:2,000), p-Creb (Cat. No. 9196, dilution 1:2,000), PEPCK1 (Cat. No. 12940, dilution 1:2,000) and p-IGF-1Rβ/ InsRβ (Cat. No. 3021, dilution 1:2,000) were obtained from Cell Signaling (Cell Signaling Technology Inc., MA, USA). G6Pase (Cat. No. ab83690, dilution 1:2,000), PPARα (Cat.No. ab24509, dilution 1:2,000) and UCP1 (Cat.No. ab10983, dilution 1:10,000) were obtained from Abcam (Abcam plc., Cambridge, UK). PGC-1α was purchased from Santa Cruz (Santa Cruz Biotechnology, Cat.No. sc-13067, 1:1,000). Antibody against GAPDH (Cat. No. GTX100118, dilution 1:10,000) was obtained from GeneTex (GeneTex Inc., CA, USA). The primary antibodies were prepared in 3% bovine albumin in Tris-buffered saline containing 0.1% (v/v) Tween 20 (TBST) and 0.05% (m/v) sodium azide with dilution factors as indicated. The anti-mouse and anti-rabbit secondary antibodies conjugated with horseradish peroxidase (HRP) were purchased from Thermo Scientific (Thermo Fisher Scientific Inc., MA, USA) and were diluted 10,000 times in 3% non-fat dry milk dissolved in TBST. Carvedilol active pharmaceutical ingredient (HPLC assay 100%) (Batch No. 16CI000002) was obtained from CTX Lifescience (CTX Lifescience Pvt Ltd., Surat, India). Protease inhibitor tablets were purchased from Thermo Fisher Scientific (Thermo Fisher Scientific Inc., MA, USA) and phosphatase inhibitor cocktail tablets were purchased from Roche (F. Hoffmann-La Roche Ltd., Basel, Switzerland). D-glucose was purchased from Intron Biotechnology (Intron Biotechnology Co., Ltd., Gyeonggi-do, Korea) and sodium pyruvate (Product. No. S024) was purchased from Toku-E (WA, USA). Bovine serum albumin (Product No. MB083) was purchased from Himedia (Mumbai, India). All other reagents were purchased from Sigma-Aldrich unless otherwise stated.

Animals

All animal experiments in this study were approved by the Institutional Animal Care and Use Committee (IACUC) of the Tan Tao University, School of Medicine (Certificate No. 02/2018-HDKH.TTU). Swiss mice were purchased from Pasteur Institute (Ho Chi Minh city, Viet Nam). The mice were kept in controlled room temperature (22 ± 1°C) with a 12-hour-light/dark cycle (light on/off at 06:00 a.m./p.m.). Mice were fed a normal chow diet (AniFood, Pasteur Institute-VN, 3.84 kcal/kg with 6–8% kcal from fat, NC) or a high fat diet (Research Diets D12492, USA, 5.24 kcal/kg with 60% kcal from fat, HFD) with filtered water provided ad libitum. After 2-week period of HFD feeding, 6-week-old male mice were administered 30 mg/kg body weight of carvedilol dissolved in 0.001M acetic acid, pH 3.8 (carvedilol treatment group, body weight 24.14 ± 0.70 grams, N = 6) or 0.001M acetic acid (vehicle controlled group, body weight 24.96 ± 0.49 grams, N = 6) via oral gavage for 4-week treatment period. Body weight and food intake were monitored daily before treatment. Blood glucose levels (fed and fasted state) and tolerance tests were measured as indicated. After experimental period, mice were sacrificed by decapitation following ketamine anesthesia (100 mg/kg body weight) and the organs and plasma samples were collected and stored at -80 oC for further analyses.

For studying the relationship between plasma leptin, insulin and norepinephrine levels, an independent cohort of 4-week-old male mice was divided into two groups and fed either NC or HFD for 8 weeks (6 mice per group, body weight 13.18 ±0.49 grams for NC-fed group and 12.86 ±0.45 grams for HFD-fed group). Blood samples were collected at the time points of 0, 4 and 8 weeks during the HFD challenging period in basal resting condition (resting state at daytime with food and water ad libitum).

Measurement of blood glucose levels

Blood samples were taken from a tail nick and glucose levels were determined by the glucose oxidase method using a commercial blood glucometer (SAFE-ACCU, Shanghai International Holding Corp., Germany). For fed state blood glucose, mice were removed from food 2 hours before measurement. To determine fasted state blood glucose, mice were fasted overnight (16 hours) with water ad libitum provided.

Glucose, insulin and pyruvate tolerance tests

Glucose (GTT), insulin (ITT) and pyruvate (PTT) tolerance tests were performed as described previously [37] after the mice were challenged with HFD and treated with carvedilol for 4 weeks. Body weight were 48.98 ± 1.22 g for HFD-fed + vehicle treatment cohort (n = 6) and 47.62 ± 0.91 g for HFD-fed + carvedilol treatment cohort (n = 6), P = 0.392. For GTT and PTT, mice were fasted overnight for 16 hours with water ad libitum provided. After measurement of fasted glucose levels, mice were intraperitoneally injected with a glucose solution (1.5 g/kg body weight) or sodium pyruvate solution (2 g/kg body weight) in normal saline. For ITT, mice were fasted for 2 hours and provided with water ad libitum. After measurement of basal glucose levels, 0.75 U/kg body weight of regular insulin (Humulin® U-100, Eli Lilly and Co., IN, USA) in normal saline was administered intraperitoneally. Blood samples were taken from a tail nick at 0, 15, 30, 60, 90, 120, and 150 minutes after injection and glucose levels were measured. The area under the curve (AUC) was determined to quantify the glucose, pyruvate and insulin tolerance.

Blood collection and plasma preparation for hormones measurement

Blood (approx. 50 μl) samples were gently collected via a tail nick using commercial EDTA-coated tubes (Microvette® CB 300, Sarstedt, Germany) and then immediately centrifuged at 10,000 rpm, 4 oC for 10 minutes. The plasma supernatants were collected and stored at -80 oC before analyzed [38, 39].

Leptin and insulin measurement

We measured plasma leptin and insulin by using ELISA kits (Cat. No. 90030 for leptin and Cat. No. 90080 for insulin, respectively, Crystal Chem, USA) in accordance with manufacturer’s instructions.

Norepinephrine measurement

Plasma norepinephrine was extracted, acylated, and then enzymatically converted before being quantitatively determined by a competitive enzyme immunoassay method using commercial ELISA kits (Cat. No. BA E-5200, Labor Diagnostika Nord GmbH & Co., Germany) followed the manufacturer’s instructions as described previously [40].

SDS-PAGE and Western blotting

Tissues from organs were homogenized using a glass Dounce homogenizer and lysed in RIPA buffer containing protease and phosphatase inhibitors. Total protein concentrations of lysed samples were determined by using PierceTM Coomassive (Bradford) Protein Assay Kit (Thermo Fisher Scientific Inc., MA, USA). 20 μg of the protein lysates was electrophoresed on SDS-PAGE gel and transferred onto nitrocellulose membranes. After blocking with 5% non-fat dry milk dissolved in TBST for 1 hour, the membranes were probed with a given primary antibody overnight at 4°C, reacted with HRP-conjugated goat anti-rabbit or anti-mouse IgG secondary antibody and were detected by using the Miracle StarTM Femto Western Blot Detection System (Intron Biotechnology Co., Ltd., Gyeonggi-do, Korea) and X-ray film (UltraCruz® Autoradiography Film, Santa Cruz Biotechnology Inc., TX, USA) or iBright CL1000 Imaging System (Thermo Fisher Scientific Inc., MA, USA). Quantification of blots (densitometry) was performed using NIH ImageJ software.

Histological analysis

White adipose tissue (WAT) and brown adipose tissue (BAT) samples were fixed in 4% formaldehyde diluted in phosphate-buffered saline (PBS) and sent to a medical center for histological analysis. Briefly, formalin-fixed tissues were dehydrated and embedded in paraffin. The paraffin-embedded sections were then cut into 4-μm slices and stained with hematoxylin and eosin (H&E). Stained slices were imaged by Dewinter Premium Digital Camera Microscope system (Dewinter Optical Inc., India). Quantification of adipocyte size from histological images was performed by an independent researcher using the NIH ImageJ Adipocytes Tool (https://github.com/MontpellierRessourcesImagerie/imagej_macros_and_scripts/wiki/Adipocytes-Tools).

Statistical analysis

The GraphPad Prism 5.0 software was used for all statistical analyses. Two-way ANOVA with Bonferroni’s post hoc tests or one-way ANOVA with Turkey’s post hoc tests or Student's t tests were used to assess the statistical difference between groups as indicated. P < 0.05 was regarded as a statistically significant difference.

Results

Basal plasma norepinephrine was elevated and highly correlated with plasma leptin in HFD-induced obesity

Leptin has been shown to promote the synthesis and release of catecholamine [15, 17–20], possibly via modulating the expression/activity of tyrosine hydroxylase, the first and rate-limiting enzyme of the catecholamine synthesis [17, 21]. Plasma leptin concentration increases in proportion to the fat mass expansion in obesity which is frequently associated with sympathetic overactivation [2]. This led us to ask whether basal plasma norepinephrine, the principal catecholamine as an index of sympathetic activity [34], elevates and correlates with plasma leptin in obesity. To examine this possibility, we employed the HFD-induced obese mouse model to assess the relationship between plasma leptin and basal norepinephrine concentrations. As shown in Fig 1A and S1 Fig, 4-weeks of the HFD challenge was sufficient to induce a typical obese condition characterized by increased body weight (Fig 1A), increased blood glucose levels, impaired glucose and insulin tolerance and adipocyte enlargement (S1A–S1D Fig). Plasma leptin was markedly increased after 4 weeks of HFD feeding and further elevated thereafter (Fig 1B). Parallel with the increase in plasma leptin, plasma norepinephrine measured in the basal resting condition was significantly increased in the HFD-fed mice and remained at high levels during HFD challenge period (Fig 1C). Moreover, linear regression analysis revealed a high positive correlation [41] between basal norepinephrine and plasma leptin (r = 0.725, P < 0.0001, Fig 1D). Although plasma insulin was also gradually increased during the development of HFD-induced obesity, there was a low correlation [41] between basal norepinephrine and plasma insulin (r = 0.428, P = 0.009, S1E and S1F Fig). These results suggested that basal norepinephrine was persistently elevated during HFD-induced obesity development and highly correlated with plasma leptin, but not plasma insulin.

Fig 1. Basal plasma norepinephrine was persistently elevated and highly correlated with plasma leptin in HFD-induced obese mice.

Fig 1

Open in a new tab

A, Body weight of male mice fed NC or HFD for 8 weeks. B, C, Plasma leptin (B) and norepinephrine (NE) (C) levels of mice measured in basal resting condition during 8-week period of HFD feeding. D, Linear correlation analysis of basal norepinephrine and plasma leptin concentrations during HFD-induced obesity. Data are presented as mean ± SEM. Two-way ANOVA with Bonferroni’s post-tests. *P< 0.05, **P<0.01 and ***P<0.001. Hormone measurement was performed in triplicate.

Hepatic glucose overproduction and muscular insulin insensitivity associated with the adrenergic overdrive in HFD-induced obesity were attenuated by carvedilol treatment

Since catecholamine has broad and complex interactions on the glucose metabolism by exerting differing effects on metabolic organs including liver, muscle and adipose tissue [33], we next investigated whether chronic elevation of basal plasma norepinephrine led to an adrenergic signaling overactivation in these organs and altered metabolic functions of HFD-fed mice. As shown in Fig 2A, 2B, 2F and 2G and S2A and S2B Fig, significant increase in levels of p-Creb, a downstream effector of the β-adrenergic receptor/cAMP signaling pathway [42], in the livers, muscles, and adipose tissues of HFD-fed mice indicated an activation of adrenergic signaling pathway in these metabolic organs following the chronic elevation of basal norepinephrine. Increased p-Creb levels were accompanied by a significant induction of the gluconeogenic enzymes, G6Pase and PEPCK1, in the livers of HFD-fed mice (Fig 2A and 2B). Consistent with increased G6Pase and PEPCK1 levels in the livers, these mice showed a hepatic glucose overproduction under pyruvate tolerance tests (PTT) compared to NC-fed mice (Fig 2C and 2D). Moreover, HFD-fed mice displayed higher plasma insulin levels without the corresponding increase of p-InsR and p-Akt levels in the muscles demonstrating a blunted muscular insulin signaling pathway (Fig 2E–2G).

Fig 2. Carvedilol treatment attenuated the hepatic glucose overproduction and muscular insulin signaling impairment associated with the HFD-induced adrenergic overdrive.

Fig 2

Open in a new tab

A, B, Immunoblots (A) and quantitative densitometry (B) showing the levels of p-Creb, G6Pase and PEPCK1 in the livers of NC-fed mice and HFD-fed mice treated with vehicle (Veh) or carvedilol (Carv). Normalized to total Creb or GAPDH. C, D, PTT (C) and PTT AUC (D) of NC-fed mice and HFD-fed mice treated with vehicle or carvedilol. E, Plasma insulin of NC-fed mice and HFD-fed mice treated with carvedilol or vehicle. F, G, Immunoblots (F) and quantitative densitometry (G) showing the levels of p-Creb, p-InsR and p-Akt in the muscles of NC-fed mice and HFD-fed mice treated with vehicle (Veh) or carvedilol (Carv). Normalized to total Creb, Akt or GAPDH. Data are presented as mean ± S.E.M. One-way ANOVA with Turkey’s post-tests in bar graphs and two-way ANOVA with Bonferroni’s post-tests in line graphs. *P< 0.05, **P<0.01 compared to NC group, #P<0.05 compared to HFD+Veh group. Hormone measurement and Western blot analysis were performed in triplicate.

We therefore designed an experiment to completely block the adrenergic overactivation in HFD-fed mice with carvedilol, a third-generation beta-blocker with additive α1-adrenoceptor antagonizing action [27, 28, 35, 36], to examine whether carvedilol treatment in HFD-induced obesity could target the adrenergic overdrive and provide metabolic benefits. As shown in Fig 2A, 2B, 2F and 2G, 30 mg/kg of body weight of carvedilol treatment completely blocked the increase of p-Creb levels in livers and muscles of the HFD-fed mice confirming the adrenergic signaling inhibition of carvedilol treatment [43]. Interestingly, carvedilol treatment was effective in suppressing the HFD-induced induction of gluconeogenic enzymes in the livers and partly corrected the hepatic glucose overproduction observed in HFD-fed mice (Fig 2A–2D). Moreover, carvedilol treatment lowered plasma insulin levels and significantly enhanced the muscular insulin signaling pathway of HFD-fed mice (Fig 2E–2G). These results indicated that carvedilol treatment targeting the adrenergic overdrive in HFD-induced obesity effectively blocked the induction of gluconeogenic enzymes to suppress a hepatic glucose overproduction and enhanced the muscular insulin signaling pathway.

Unlike the results observed in livers and muscles of the carvedilol-treated mice, we found that carvedilol failed to suppress the HFD-induced increase of p-Creb levels in the brown adipose tissues (BAT) of HFD-fed mice (S2A and S2B Fig). In addition, levels of PGC1α, PPARα, and UCP1 which are molecular clues of lipid catabolism in the BAT samples [44] were not different between HFD-fed mice treated with carvedilol and vehicle control (S2A and S2B Fig). Moreover, we did not observe a significant change in the adipocyte size of BAT samples between these mice (S2C Fig). These results suggested that carvedilol treatment might not affect the brown fat metabolism in HFD-fed mice.

Carvedilol treatment during HFD-induced obesity reduced white adipose tissue enlargement and improved glucose tolerance and insulin sensitivity without affecting body weight and blood glucose levels

We next investigated whether the beneficial effects of carvedilol on gluconeogenic enzymes, hepatic glucose production and muscular insulin signaling pathway were translated to the metabolic benefits of carvedilol treatment in HFD-induced obesity. Indeed, carvedilol treatment did not affect the body weight and total daily food intake of HFD-fed mice (Fig 3A and 3B), however, the HFD-fed mice treated with carvedilol for 4 weeks showed reduced white adipose tissue (WAT) enlargement compared to the vehicle-treated mice (Fig 3C). Consistent with reduced WAT enlargement, plasma leptin levels of carvedilol-treated mice were significantly lower than those of controlled mice (Fig 3D).

Fig 3. Carvedilol treatment in HFD-fed mice reduced white adipose tissue enlargement and plasma leptin without affecting food consumption and body weight.

Fig 3

Open in a new tab

A, Body weight of HFD-fed mice treated with vehicle (veh) or carvedilol (carv). B, Total daily food intake of HFD-fed mice treated with vehicle (veh) or carvedilol (carv) measured in 3 consecutive days. C, Representative figures of H&E staining (left) and quantification of white adipocyte size (right) of HFD-fed mice treated with vehicle or carvedilol. Scale bar, 100 μm. D, Plasma leptin levels of mice before and after carvedilol treatment. Data are presented as mean ± S.E.M. Student’s t-tests in bar graphs and two-way ANOVA in line graphs. Hormone measurement and histological analysis were performed in triplicate.

Interestingly, we did not observe any differences in the blood glucose levels in both fed and fasted state between these mice (S3 Fig). However, HFD-fed mice treated with carvedilol showed improved glucose tolerance (Fig 4A and 4B) and insulin sensitivity (Fig 4C and 4D) during glucose and insulin tolerance tests (GTT and ITT). These metabolic effects of carvedilol treatment could be attributed to its beneficial effects on the gluconeogenesis (Fig 2A–2D) and insulin signaling pathway (Fig 2E–2G), but not due to a change in energy consumption (Fig 3B). Taken together, these results suggested that carvedilol treatment targeting the adrenergic overactivation in HFD-induced obese mice helped to improve glucose tolerance and insulin sensitivity without affecting body weight and blood glucose levels.

Fig 4. Carvedilol treatment targeting the adrenergic overactivation in HFD-fed mice improved glucose tolerance and insulin sensitivity.

Fig 4

Open in a new tab

A, B, GTT (A) and GTT AUC (B) of HFD-fed mice treated with vehicle or carvedilol. C, D, ITT (C) and ITT AUC (D) of mice. Data are presented as mean ± S.E.M. Student’s t-tests in bar graphs and two-way ANOVA with Bonferroni’s post-tests in line graphs. *P< 0.05.

Discussion

Using the HFD-induced obese mouse model, we observed a chronic excess of the basal plasma norepinephrine along with increasing plasma leptin levels during obesity development. This persisted elevation of basal plasma norepinephrine further highlighted an overactivation of the SNS which has been previously documented in obesity [2]. Interestingly, basal norepinephrine was well-correlated with the plasma leptin, but not plasma insulin in obesity. The results in our study were consistent with recent findings that leptin, but not insulin, mediated the SNS-driven increase in heart rate and blood pressure associated with obesity [10]. Moreover, since leptin has been shown to directly stimulate the catecholamine synthesis and secretion [15, 17–20], there might be a direct link between increased basal norepinephrine and the hyperleptinemic condition in obesity. However, further studies are required to confirm the causally direct relationship between basal norepinephrine and plasma leptin.

Excessive catecholamine representing an adrenergic hyperactivity is known to cause profoundly adverse effects on glucose metabolism [23, 25, 26, 45]. However, logically targeting the adrenergic overdrive in obesity by using adrenergic receptor antagonists in order to attenuate the metabolic disorders seems debatable since clinical evidence of the traditional beta-blockers showed negative effects on body metabolism possibly due to their incomplete adrenoceptor blockade properties [29, 30]. In the current study, we used carvedilol, a third-generation beta-blocker agent with vasodilating action [35, 36] which can completely block the effects of excessive catecholamine, to investigate whether therapeutically targeting the adrenergic overdrive from chronic excess of basal norepinephrine in obesity could lead to metabolic benefits on the glucose metabolism. In agreement with the results from recent clinical studies [31, 33, 46], we found that carvedilol treatment during HFD-induced obesity improved glucose tolerance and insulin sensitivity possibly by suppressing the hepatic glucose overproduction and enhancing the muscular insulin signaling pathway.

Unlike the results from a previous study showing that carvedilol had a hyperglycemic effect [47], our study showed that carvedilol treatment did not affect neither blood glucose levels nor body weight of the HFD-fed mice. Our findings of carvedilol’s effects on blood glucose levels and glucose tolerance were consistent with the metabolic parameters of HFD-fed mice treated with carvedilol in a study of Wang et al. in which they used carvedilol to investigate diabetes-associated cardiac dysfunction [43]. The inconsistent findings on blood glucose of carvedilol treatment might be due to differences in the treatment time periods and/or the experimental rodent models since Wang et al. and our study used HFD-induced obese mice and treated carvedilol for 4 weeks [43] while Suresha et al. treated carvedilol in normal albino rats for only a 5-day period [47]. Nonetheless, our findings and others consistently indicated that the use of carvedilol in obesity might provide long-term benefits on glucose metabolism. Indirectly, these findings also further highlighted a previous notion that an obesity-associated sympathetic disorder as observed in our study by a chronic excess of basal norepinephrine in HFD-fed mice could, at least, partly contribute to the pathophysiology of metabolic disorders [6, 7].

Chronic adrenergic overdrive from excessive catecholamine might adversely affect the insulin sensitivity and glucose metabolism via complex interactions in several metabolic organs including increased lipolysis, impaired muscular glucose uptake, and increased hepatic glucose production [4–6]. By characterizing the primary targets of carvedilol treatment on suppression of hepatic glucose overproduction and enhancement of muscular insulin signaling, our study provided mechanistic insights into the metabolic benefits of carvedilol treatment in obese subjects. These metabolic benefits of carvedilol might be attributed to its ability to block the adrenergic overactivation in obesity since increased p-Creb levels in livers and muscles of the HFD-fed mice were totally blunted by carvedilol treatment. In contrast, the histological analysis and molecular markers of lipid metabolism in BAT samples were not changed by carvedilol treatment suggesting that effect of carvedilol on brown fat metabolism seemed minimal. Because carvedilol has been shown to have affinity with β3-adrenoceptors in adipose tissues [48] and we found that the HFD-induced WAT enlargement was reduced by carvedilol treatment, our study therefore could not totally rule out carvedilol’s actions in adipose tissues. In this regard, however, it would be interesting to examine whether carvedilol (and other third-generation beta-blockers with metabolic benefits) can specifically block the sympathetic hyperactivity to metabolic organs in different manners.

Conclusions

The adrenergic overdrive which has been supposed to contribute to the pathogenesis of cardiovascular complications and metabolic disorders in obesity might directly connect to the increasing plasma leptin concentration [6–8]. Beta-blockers which can completely block the adrenergic overactivation might overcome the negative effects of traditional beta-blockers on glucose metabolism and insulin sensitivity [31]. In this regard, our study further provided an in vivo evidence of the relationship between chronic catecholamine excess and the hyperleptinemic condition in obesity and underpinned the view that therapeutic target of the chronic adrenergic overdrive in obesity by third-generation beta-blockers such as carvedilol might be helpful to attenuate obesity-related metabolic disorders.

Supporting information

S1 Fig. Metabolic characterization of HFD-induced obese mice and correlation of basal norepinephrine and plasma insulin levels.

A, Blood glucose levels at fed (left) and fasted state (right) of mice fed NC or HFD.

B, C, GTT (B) and ITT (C) of mice performed after 4 weeks feeding NC or HFD.

D, Representative figures of H&E staining (left) and quantification of adipocyte size (right) of white and brown adipose tissues of mice fed NC or HFD. Scale bar, 100 μm in WAT and 50 μm in BAT.

E, Plasma insulin levels of mice during 8-week period feeding NC or HFD.

F, Linear correlation analysis of basal plasma norepinephrine and insulin concentrations during HFD-induced obesity.

Data are presented as mean ± S.E.M. Student’s t-tests in bar graphs and two-way ANOVA with Bonferroni’s post-tests in line graphs. *P< 0.05, **P<0.01, ***P<0.001. Hormone measurement and histological analysis were performed in triplicate.

(PDF)

Click here for additional data file. (4.5MB, pdf)
S2 Fig. Molecular markers of fat metabolism and histological analysis of BAT samples of HFD-fed mice treated with carvedilol.

A, B, Immunoblots and quantitative densitometry (B) showing the levels of p-Creb, PGC1α, PPARα and UCP1 in BAT samples of NC-fed mice and HFD-fed mice treated with vehicle (Veh) or carvedilol (Carv). Normalized to total Creb or GAPDH.

C, Representative figures of H&E staining (left) and quantification of brown adipocyte size (right) of HFD-fed mice treated with vehicle or carvedilol. Scale bar, 50 μm.

Data are presented as mean ± S.E.M. Student’s t-tests or one-way ANOVA with Turkey’s post-tests in bar graphs. *P<0.05. Western blot and histological analyses were performed in triplicate.

(PDF)

Click here for additional data file. (4.8MB, pdf)
S3 Fig. Carvedilol treatment did not affect blood glucose levels of HFD-fed mice.

Blood glucose levels at fed state (left) and fasted state (right) of HFD-fed mice treated with vehicle or carvedilol.

Data are presented as mean ± S.E.M. Student’s t-tests.

(PDF)

Click here for additional data file. (292.4KB, pdf)
S4 Fig. Original uncropped and unadjusted images of blots.

(PDF)

Click here for additional data file. (3.8MB, pdf)

Acknowledgments

We thank Mr. Nguyen Huu Dung (Pharmacist, R&D Boston Pharmaceutical Co., Viet Nam) for his generous providing of carvedilol active pharmaceutical ingredient. We are grateful to Mr. Isaac Smith (M.A, School of Humanities and Languages, Tan Tao University, Viet Nam) for his language editing of the manuscript.

Data Availability

All relevant data are within the paper and Supporting Information files.

Funding Statement

This research was funded by the Viet Nam National Foundation for Science and Technology (NAFOSTED 108.05-2017.01 to KVD), URL: https://nafosted.gov.vn/en/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766–81. 10.1016/S0140-6736(14)60460-8 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Smith MM, Minson CT. Obesity and adipokines: effects on sympathetic overactivity. J Physiol. 2012;590(8):1787–801. Epub 2012/02/22. 10.1113/jphysiol.2011.221036 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991–1006. 10.1161/CIRCRESAHA.116.305697 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Seravalle G, Grassi G. Sympathetic Nervous System, Hypertension, Obesity and Metabolic Syndrome. High Blood Press Cardiovasc Prev. 2016;23(3):175–9. Epub 2016/03/05. 10.1007/s40292-016-0137-4 . [DOI] [PubMed] [Google Scholar]
  • 5.Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens. 2007;25(5):909–20. Epub 2007/04/07. 10.1097/HJH.0b013e328048d004 . [DOI] [PubMed] [Google Scholar]
  • 6.Schlaich M, Straznicky N, Lambert E, Lambert G. Metabolic syndrome: a sympathetic disease? Lancet Diabetes Endocrinol. 2015;3(2):148–57. Epub 2014/04/16. 10.1016/S2213-8587(14)70033-6 . [DOI] [PubMed] [Google Scholar]
  • 7.Moreira MC, Pinto IS, Mourao AA, Fajemiroye JO, Colombari E, Reis AA, et al. Does the sympathetic nervous system contribute to the pathophysiology of metabolic syndrome? Front Physiol. 2015;6:234 Epub 2015/09/18. 10.3389/fphys.2015.00234 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Osorio J. Obesity: The many faces of leptin—a novel role for leptin signalling in obesity-induced hypertension. Nat Rev Endocrinol. 2015;11(3):129 10.1038/nrendo.2014.231 . [DOI] [PubMed] [Google Scholar]
  • 9.Simonds SE, Cowley MA. Hypertension in obesity: is leptin the culprit? Trends Neurosci. 2013;36(2):121–32. 10.1016/j.tins.2013.01.004 . [DOI] [PubMed] [Google Scholar]
  • 10.Simonds SE, Pryor JT, Ravussin E, Greenway FL, Dileone R, Allen AM, et al. Leptin mediates the increase in blood pressure associated with obesity. Cell. 2014;159(6):1404–16. 10.1016/j.cell.2014.10.058 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Luan B, Goodarzi MO, Phillips NG, Guo X, Chen YD, Yao J, et al. Leptin-mediated increases in catecholamine signaling reduce adipose tissue inflammation via activation of macrophage HDAC4. Cell metabolism. 2014;19(6):1058–65. 10.1016/j.cmet.2014.03.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Zeng W, Pirzgalska RM, Pereira MM, Kubasova N, Barateiro A, Seixas E, et al. Sympathetic neuro-adipose connections mediate leptin-driven lipolysis. Cell. 2015;163(1):84–94. 10.1016/j.cell.2015.08.055 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Carlyle M, Jones OB, Kuo JJ, Hall JE. Chronic cardiovascular and renal actions of leptin: role of adrenergic activity. Hypertension. 2002;39(2 Pt 2):496–501. 10.1161/hy0202.104398 . [DOI] [PubMed] [Google Scholar]
  • 14.Mark AL, Agassandian K, Morgan DA, Liu X, Cassell MD, Rahmouni K. Leptin signaling in the nucleus tractus solitarii increases sympathetic nerve activity to the kidney. Hypertension. 2009;53(2):375–80. 10.1161/HYPERTENSIONAHA.108.124255 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Takekoshi K, Motooka M, Isobe K, Nomura F, Manmoku T, Ishii K, et al. Leptin directly stimulates catecholamine secretion and synthesis in cultured porcine adrenal medullary chromaffin cells. Biochemical and biophysical research communications. 1999;261(2):426–31. 10.1006/bbrc.1999.1025 . [DOI] [PubMed] [Google Scholar]
  • 16.Takekoshi K, Ishii K, Kawakami Y, Isobe K, Nanmoku T, Nakai T. Ca(2+) mobilization, tyrosine hydroxylase activity, and signaling mechanisms in cultured porcine adrenal medullary chromaffin cells: effects of leptin. Endocrinology. 2001;142(1):290–8. 10.1210/endo.142.1.7914 . [DOI] [PubMed] [Google Scholar]
  • 17.Takekoshi K, Ishii K, Nanmoku T, Shibuya S, Kawakami Y, Isobe K, et al. Leptin stimulates catecholamine synthesis in a PKC-dependent manner in cultured porcine adrenal medullary chromaffin cells. Endocrinology. 2001;142(11):4861–71. 10.1210/endo.142.11.8484 . [DOI] [PubMed] [Google Scholar]
  • 18.Utsunomiya K, Yanagihara N, Tachikawa E, Cheah TB, Kajiwara K, Toyohira Y, et al. Stimulation of catecholamine synthesis in cultured bovine adrenal medullary cells by leptin. Journal of neurochemistry. 2001;76(3):926–34. 10.1046/j.1471-4159.2001.00123.x . [DOI] [PubMed] [Google Scholar]
  • 19.Shibuya I, Utsunomiya K, Toyohira Y, Ueno S, Tsutsui M, Cheah TB, et al. Regulation of catecholamine synthesis by leptin. Annals of the New York Academy of Sciences. 2002;971:522–7. 10.1111/j.1749-6632.2002.tb04517.x . [DOI] [PubMed] [Google Scholar]
  • 20.Satoh N, Ogawa Y, Katsuura G, Numata Y, Tsuji T, Hayase M, et al. Sympathetic activation of leptin via the ventromedial hypothalamus: leptin-induced increase in catecholamine secretion. Diabetes. 1999;48(9):1787–93. 10.2337/diabetes.48.9.1787 . [DOI] [PubMed] [Google Scholar]
  • 21.Son DH, Doan KV, Yang DJ, Sun JS, Kim SK, Kang N, et al. FoxO1 regulates leptin-induced mood behavior by targeting tyrosine hydroxylase. Metabolism. 2018. Epub 2018/12/01. 10.1016/j.metabol.2018.11.013 . [DOI] [PubMed] [Google Scholar]
  • 22.Kvetnansky R, Sabban EL, Palkovits M. Catecholaminergic systems in stress: structural and molecular genetic approaches. Physiological reviews. 2009;89(2):535–606. 10.1152/physrev.00042.2006 . [DOI] [PubMed] [Google Scholar]
  • 23.Goldstein DS. The Autonomic Nervous System in Health and Disease (Neurological Disease and Therapy). New York: CRC Press; 2000. [Google Scholar]
  • 24.Spiegel A, Kalinkovich A, Shivtiel S, Kollet O, Lapidot T. Stem cell regulation via dynamic interactions of the nervous and immune systems with the microenvironment. Cell stem cell. 2008;3(5):484–92. 10.1016/j.stem.2008.10.006 . [DOI] [PubMed] [Google Scholar]
  • 25.Petrak O, Haluzikova D, Kavalkova P, Strauch B, Rosa J, Holaj R, et al. Changes in energy metabolism in pheochromocytoma. J Clin Endocrinol Metab. 2013;98(4):1651–8. Epub 2013/02/26. 10.1210/jc.2012-3625 . [DOI] [PubMed] [Google Scholar]
  • 26.Barth E, Albuszies G, Baumgart K, Matejovic M, Wachter U, Vogt J, et al. Glucose metabolism and catecholamines. Crit Care Med. 2007;35(9 Suppl):S508–18. Epub 2007/09/22. 10.1097/01.CCM.0000278047.06965.20 . [DOI] [PubMed] [Google Scholar]
  • 27.Weber MA. The role of the new beta-blockers in treating cardiovascular disease. American journal of hypertension. 2005;18(12 Pt 2):169S–76S. 10.1016/j.amjhyper.2005.09.009 . [DOI] [PubMed] [Google Scholar]
  • 28.Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al. Beta-blockers for hypertension. The Cochrane database of systematic reviews. 2007;(1):CD002003 10.1002/14651858.CD002003.pub2 . [DOI] [PubMed] [Google Scholar]
  • 29.Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003. 10.1016/S0140-6736(02)08089-3 . [DOI] [PubMed] [Google Scholar]
  • 30.Ripley TL, Saseen JJ. beta-blockers: a review of their pharmacological and physiological diversity in hypertension. The Annals of pharmacotherapy. 2014;48(6):723–33. 10.1177/1060028013519591 . [DOI] [PubMed] [Google Scholar]
  • 31.Deedwania P. Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating beta-blockers. Journal of clinical hypertension. 2011;13(1):52–9. 10.1111/j.1751-7176.2010.00386.x . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Reisin E, Owen J. Treatment: special conditions. Metabolic syndrome: obesity and the hypertension connection. Journal of the American Society of Hypertension : JASH. 2015;9(2):156–9; quiz 60. 10.1016/j.jash.2014.12.015 . [DOI] [PubMed] [Google Scholar]
  • 33.Kveiborg B, Christiansen B, Major-Petersen A, Torp-Pedersen C. Metabolic effects of beta-adrenoceptor antagonists with special emphasis on carvedilol. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2006;6(4):209–17. 10.2165/00129784-200606040-00001 . [DOI] [PubMed] [Google Scholar]
  • 34.Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens. 1999;17(6):719–34. Epub 1999/08/25. 10.1097/00004872-199917060-00001 . [DOI] [PubMed] [Google Scholar]
  • 35.Feuerstein GZ, Ruffolo RR Jr. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J. 1995;16 Suppl F:38–42. Epub 1995/07/01. 10.1093/eurheartj/16.suppl_f.38 . [DOI] [PubMed] [Google Scholar]
  • 36.Stoschitzky K, Koshucharova G, Zweiker R, Maier R, Watzinger N, Fruhwald FM, et al. Differing beta-blocking effects of carvedilol and metoprolol. Eur J Heart Fail. 2001;3(3):343–9. Epub 2001/05/30. 10.1016/s1388-9842(01)00126-x . [DOI] [PubMed] [Google Scholar]
  • 37.Kinyua AW, Ko CM, Doan KV, Yang DJ, Huynh MKQ, Moh SH, et al. 4-hydroxy-3-methoxycinnamic acid regulates orexigenic peptides and hepatic glucose homeostasis through phosphorylation of FoxO1. Exp Mol Med. 2018;50(2):e437 Epub 2018/02/03. 10.1038/emm.2017.253 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Boomsma F, Alberts G, van Eijk L, Man in 't Veld AJ, Schalekamp MA. Optimal collection and storage conditions for catecholamine measurements in human plasma and urine. Clinical chemistry. 1993;39(12):2503–8. . [PubMed] [Google Scholar]
  • 39.Denfeld QE, Habecker BA, Woodward WR. Measurement of plasma norepinephrine and 3,4-dihydroxyphenylglycol: method development for a translational research study. BMC research notes. 2018;11(1):248 10.1186/s13104-018-3352-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Doan KV, Kinyua AW, Yang DJ, Ko CM, Moh SH, Shong KE, et al. FoxO1 in dopaminergic neurons regulates energy homeostasis and targets tyrosine hydroxylase. Nat Commun. 2016;7:12733 Epub 2016/09/30. 10.1038/ncomms12733 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Mukaka MM. Statistics corner: A guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012;24(3):69–71. Epub 2013/05/03. [PMC free article] [PubMed] [Google Scholar]
  • 42.Woo AY, Xiao RP. beta-Adrenergic receptor subtype signaling in heart: from bench to bedside. Acta pharmacologica Sinica. 2012;33(3):335–41. 10.1038/aps.2011.201 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Wang Q, Liu Y, Fu Q, Xu B, Zhang Y, Kim S, et al. Inhibiting Insulin-Mediated beta2-Adrenergic Receptor Activation Prevents Diabetes-Associated Cardiac Dysfunction. Circulation. 2017;135(1):73–88. 10.1161/CIRCULATIONAHA.116.022281 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Seale P. Transcriptional Regulatory Circuits Controlling Brown Fat Development and Activation. Diabetes. 2015;64(7):2369–75. 10.2337/db15-0203 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Snitker S, Macdonald I, Ravussin E, Astrup A. The sympathetic nervous system and obesity: role in aetiology and treatment. Obesity reviews : an official journal of the International Association for the Study of Obesity. 2000;1(1):5–15. 10.1046/j.1467-789x.2000.00001.x . [DOI] [PubMed] [Google Scholar]
  • 46.Ahmad A. Carvedilol can Replace Insulin in the Treatment of Type 2 Diabetes Mellitus. Journal of Diabetes & Metabolism. 2017;8(2). 10.4172/2155-6156.1000726 [DOI] [Google Scholar]
  • 47.R NS, V A, B P, H LK, A MS, V HP, et al. The effect of carvedilol on blood glucose levels in normal albino rats. J Clin Diagn Res. 2013;7(9):1900–3. 10.7860/JCDR/2013/6435.3346 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Schnabel P, Maack C, Mies F, Tyroller S, Scheer A, Bohm M. Binding properties of beta-blockers at recombinant beta1-, beta2-, and beta3-adrenoceptors. Journal of cardiovascular pharmacology. 2000;36(4):466–71. 10.1097/00005344-200010000-00008 . [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Dong-Gyu Jo

5 Sep 2019

PONE-D-19-21383

Carvedilol Improves Glucose Tolerance and Insulin Sensitivity in Treatment of Adrenergic Overdrive in High Fat Diet-induced Obesity

PLOS ONE

Dear Dr. Doan,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Oct 20 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Dong-Gyu Jo, Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. During your revisions, please note that a simple title correction is required: "Carvedilol Improves Glucose Tolerance and Insulin Sensitivity in Treatment of Adrenergic Overdrive in High Fat Diet-induced Obesity *in mice*". Please ensure this is updated both in the manuscript file and the online submission information.

3. To comply with PLOS ONE submissions requirements, in your Methods section, please provide additional information on the animal research and ensure you have included details on (i) methods of sacrifice, (ii) methods of anesthesia and/or analgesia, and (iii) efforts to alleviate suffering.

4. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In the manuscript entitled “Carvedilol Improves Glucose Tolerance and Insulin Sensitivity in Treatment of Adrenergic Overdrive in High Fat Diet-induced Obesity”, Nguyen et al. have investigated the metabolic effects of carvedilol, a third-generation beta-blocker agent, in the HFD-induced obese mice in which they found that the basal plasma norepinephrine of those mice is chronically elevated and correlated to the plasma leptin concentrations. They showed that treatment of adrenergic overactivation from the excessive norepinephrine in HFD-fed mice with carvedilol enhances glucose tolerance and insulin sensitivity by blocking the glucose overproduction in the liver and increasing muscular insulin sensitivity. Overall, the manuscript appears very solid and well done. The manuscript would benefit from addressing following points:

(1) The p-Creb level should be assessed together with total Creb level in addition to the loading protein in the samples.

(2) In Figure 2B, G and Figure S2B, the unit of Y-axis should be provided.

(3) In Figure S1D, the scale bar does not correspond to the absolute readings in the bar graphs. The authors should revise it.

Reviewer #2: This study submitted by Nguyen et al. claims that adrenergic overdrive such as high level of catecholamine link to plasma leptin level, consequently it contributes to the genesis of metabolic disorder. Nguyen et al. found that basal norepinephrine level is increased with a strong correlation of plasma leptin concentration in high-fat diet (HFD)-induced obese mouse model. By treating carvedilol, a third-generation beta type blocker, in HFD-induced obese mouse, the glucose tolerance and insulin sensitivity were improved.

This study is well designed and formed. Particularly Nguyen et al. carefully propose important point regarding potential causation of metabolic disorder which is the correlation between adrenergic overdrive and plasma leptin level, and they verified the effect of carvedilol against adrenergic overdrive.

I have an only minor comment regarding this study.

Figure legend should describe how many (N=??) repeat each experiment regardless of its type including western blot and its analysis. Although figure itself has displayed a number which I assume is an experimental number.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2019 Nov 4;14(11):e0224674. doi: 10.1371/journal.pone.0224674.r002

Author response to Decision Letter 0

26 Sep 2019

Rebuttal Letter (PONE-D-19-21383)

We sincerely appreciate the Academic Editor and Reviewers for taking your valuable time to consider our work. Here, we would like to address the journal requirements from the academic editor and the reviewer’s comments as follows:

Journal Requirements:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response:

We have formatted the manuscript following PLOS ONE's style requirements. Additionally, for this reason, we have rearranged the Figure 3 and Supplemental Figure 3 to make 04 main figures in the revised manuscript. We have therefore updated the Figs 3 and 4 and S3 Fig and the text in the “Results” and “Figure legends” sections in the revised manuscript correspondingly (lines 273-291, 537-553 and 584-587).

2. During your revisions, please note that a simple title correction is required: "Carvedilol Improves Glucose Tolerance and Insulin Sensitivity in Treatment of Adrenergic Overdrive in High Fat Diet-induced Obesity *in mice*". Please ensure this is updated both in the manuscript file and the online submission information.

Response:

We have corrected and updated the title “Carvedilol improves glucose tolerance and insulin sensitivity in treatment of adrenergic overdrive in high fat diet-induced obesity in mice” both in the revised manuscript (line 2) and the online submission information as the Academic Editor suggested.

We sincerely appreciate the Academic Editor for this insightful correction to better clarify our findings.

3. To comply with PLOS ONE submissions requirements, in your Methods section, please provide additional information on the animal research and ensure you have included details on (i) methods of sacrifice, (ii) methods of anesthesia and/or analgesia, and (iii) efforts to alleviate suffering.

Response:

We apologize the Academic Editor for the missing information of animal research on (i) methods of sacrifice, (ii) methods of anesthesia and/or analgesia, and (iii) efforts to alleviate suffering in the “Methods” section. We sacrificed mice by decapitation after anesthetizing with ketamine. We have provided this detail information in the “Methods” section in the revised manuscript (lines 131-132).

4. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

Response:

We have provided the original uncropped and unadjusted images of all blots/gels in the S4 Fig of the Supporting Information file.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Response:

We sincerely appreciate the reviewer’s comment and suggestion on our manuscript.

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Response:

We sincerely appreciate the reviewer’s comment and suggestion on our manuscript.

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Response:

We sincerely appreciate the reviewer’s comment and suggestion on our manuscript.

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Response:

We sincerely appreciate the reviewer’s comment and suggestion on our manuscript.

5. Review Comments to the Author

Reviewer #1:

In the manuscript entitled “Carvedilol Improves Glucose Tolerance and Insulin Sensitivity in Treatment of Adrenergic Overdrive in High Fat Diet-induced Obesity”, Nguyen et al. have investigated the metabolic effects of carvedilol, a third-generation beta-blocker agent, in the HFD-induced obese mice in which they found that the basal plasma norepinephrine of those mice is chronically elevated and correlated to the plasma leptin concentrations. They showed that treatment of adrenergic overactivation from the excessive norepinephrine in HFD-fed mice with carvedilol enhances glucose tolerance and insulin sensitivity by blocking the glucose overproduction in the liver and increasing muscular insulin sensitivity. Overall, the manuscript appears very solid and well done. The manuscript would benefit from addressing following points:

(1) The p-Creb level should be assessed together with total Creb level in addition to the loading protein in the samples.

Response:

We agree with the reviewer that the p-Creb level should be measured together with total Creb. We have therefore run the samples to check total Creb levels and provided the results in the Figs 2A, F and S2A Fig in the revised manuscript. Similar to the loading protein GAPDH in the samples, the levels of total Creb were comparable between control and carvedilol treatment groups. Further, we have updated the Figs 2A-B, F-G and S2A and B Fig using the ratios of p-Creb/total Creb correspondingly. We thank the reviewer for this insightful suggestion.

(2) In Figure 2B, G and Figure S2B, the unit of Y-axis should be provided.

Response:

We apologize the reviewer for the missing information on the unit of Y-axis in the Figure 2B, G and Figure S2B. We have updated the Fig 2B, G and S2B Fig providing the unit of Y-axis in the revised manuscript. We sincerely thank the reviewer for this comment.

(3) In Figure S1D, the scale bar does not correspond to the absolute readings in the bar graphs. The authors should revise it.

Response:

We apologize the reviewer for the confusing correspondence between scale bar and absolute readings in the bar graphs in Figure S1D. We have revised the quantification of histological images and updated the results in the S1D Fig in the revised manuscript correspondingly. We sincerely appreciate the reviewer for this insightful comment to improve our manuscript.

Reviewer #2:

This study submitted by Nguyen et al. claims that adrenergic overdrive such as high level of catecholamine link to plasma leptin level, consequently it contributes to the genesis of metabolic disorder. Nguyen et al. found that basal norepinephrine level is increased with a strong correlation of plasma leptin concentration in high-fat diet (HFD)-induced obese mouse model. By treating carvedilol, a third-generation beta type blocker, in HFD-induced obese mouse, the glucose tolerance and insulin sensitivity were improved.

This study is well designed and formed. Particularly Nguyen et al. carefully propose important point regarding potential causation of metabolic disorder which is the correlation between adrenergic overdrive and plasma leptin level, and they verified the effect of carvedilol against adrenergic overdrive.

I have an only minor comment regarding this study.

Figure legend should describe how many (N=??) repeat each experiment regardless of its type including western blot and its analysis. Although figure itself has displayed a number which I assume is an experimental number.

Response:

We apologize the reviewer for missing information on the experimental replication in the figure legends. We performed the experiments of hormone measurement, histological and western blot analyses in triplicate. We have updated the figure legends to describe information on the replication of each experiment in the revised manuscript correspondingly (lines 518, 534-535, 546, 569-570 and 581-582). We appreciate the reviewer for this insightful and constructive suggestion.

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Response:

We sincerely appreciate the reviewer’s comment and suggestion on our manuscript.

We sincerely thank the reviewers for the careful reading and insightful comments on our manuscript.

Sincerely,

Khanh V. Doan, Ph.D.,

Department of Pharmacology,

School of Medicine, Tan Tao University.

Address: Tan Tao University Ave., Tan Duc E.City, Duc Hoa, Long An 850000, Viet Nam.

Tel: (+84-272)-376-9216

Fax: (+84-272)-376-9208

Cell: (+84-91)-185-1177

Email: doankhanh.pharm@gmail.com

Attachment

Submitted filename: Response to Reviewers.doc

Click here for additional data file. (70.5KB, doc)

Decision Letter 1

Dong-Gyu Jo

21 Oct 2019

Carvedilol improves glucose tolerance and insulin sensitivity in treatment of adrenergic overdrive in high fat diet-induced obesity in mice

PONE-D-19-21383R1

Dear Dr. Doan,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Dong-Gyu Jo, Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Dong-Gyu Jo

24 Oct 2019

PONE-D-19-21383R1

Carvedilol improves glucose tolerance and insulin sensitivity in treatment of adrenergic overdrive in high fat diet-induced obesity in mice

Dear Dr. Doan:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Dong-Gyu Jo

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Metabolic characterization of HFD-induced obese mice and correlation of basal norepinephrine and plasma insulin levels.

    A, Blood glucose levels at fed (left) and fasted state (right) of mice fed NC or HFD.

    B, C, GTT (B) and ITT (C) of mice performed after 4 weeks feeding NC or HFD.

    D, Representative figures of H&E staining (left) and quantification of adipocyte size (right) of white and brown adipose tissues of mice fed NC or HFD. Scale bar, 100 μm in WAT and 50 μm in BAT.

    E, Plasma insulin levels of mice during 8-week period feeding NC or HFD.

    F, Linear correlation analysis of basal plasma norepinephrine and insulin concentrations during HFD-induced obesity.

    Data are presented as mean ± S.E.M. Student’s t-tests in bar graphs and two-way ANOVA with Bonferroni’s post-tests in line graphs. *P< 0.05, **P<0.01, ***P<0.001. Hormone measurement and histological analysis were performed in triplicate.

    (PDF)

    Click here for additional data file. (4.5MB, pdf)
    S2 Fig. Molecular markers of fat metabolism and histological analysis of BAT samples of HFD-fed mice treated with carvedilol.

    A, B, Immunoblots and quantitative densitometry (B) showing the levels of p-Creb, PGC1α, PPARα and UCP1 in BAT samples of NC-fed mice and HFD-fed mice treated with vehicle (Veh) or carvedilol (Carv). Normalized to total Creb or GAPDH.

    C, Representative figures of H&E staining (left) and quantification of brown adipocyte size (right) of HFD-fed mice treated with vehicle or carvedilol. Scale bar, 50 μm.

    Data are presented as mean ± S.E.M. Student’s t-tests or one-way ANOVA with Turkey’s post-tests in bar graphs. *P<0.05. Western blot and histological analyses were performed in triplicate.

    (PDF)

    Click here for additional data file. (4.8MB, pdf)
    S3 Fig. Carvedilol treatment did not affect blood glucose levels of HFD-fed mice.

    Blood glucose levels at fed state (left) and fasted state (right) of HFD-fed mice treated with vehicle or carvedilol.

    Data are presented as mean ± S.E.M. Student’s t-tests.

    (PDF)

    Click here for additional data file. (292.4KB, pdf)
    S4 Fig. Original uncropped and unadjusted images of blots.

    (PDF)

    Click here for additional data file. (3.8MB, pdf)
    Attachment

    Submitted filename: Response to Reviewers.doc

    Click here for additional data file. (70.5KB, doc)

    Data Availability Statement

    All relevant data are within the paper and Supporting Information files.

    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES